NEW IN VITRO INTEGRATED APPROACH TO PHARMACO-TOXICOLOGY AND METABOLISM IN CANCER THERAPY. STRUCTURE-ACTIVITY REQUIREMENTS OF ECTONUCLEOTIDASES

Projektinformationen

ID Finanzhilfevereinbarung: BAP*0471

Startdatum 1 Januar 1989

Enddatum 31 Dezember 1990

Finanziert unter

• Multiannual research action programme (EEC) in the field of biotechnology (BAP), 1985-1989

Gesamtkosten € 0,00

EU-Beitrag Keine Daten

Koordiniert durch

CENTRO DE INVESTIGACION DEL HOSPITAL DE LA FE "SEVASA"
Spain

Ziel

Predictive in vitro models have been developed for assessing the therapeutic efficiency and the toxicity (mainly hepatoxicity), including metabolic profiles of anticancer drugs. These include: improving methods for primary culture of human cancer cells; selecting multidrug resistant human cancer cell lines; isolation, cryopreservation and culture of human hepatocytes; development of an organ slicing technique. The integrated set of in vitro models are routinely used in drug development.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › multidrug resistance

Programm/Programme

• FP1-BAP - Multiannual research action programme (EEC) in the field of biotechnology (BAP), 1985-1989

Thema/Themen

Data not available

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

CSC - Cost-sharing contracts

Koordinator

CENTRO DE INVESTIGACION DEL HOSPITAL DE LA FE "SEVASA"

• EU-Beitrag: Keine Daten
• Adresse: HOSPITAL DE LA FE "SEVASA" AVDA.DE CAMPANAR 21 ; 46009 VALENCIA ; Spanien
• Gesamtkosten: Keine Daten